Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-site cefazolin concentrations in foot and ankle surgery
NL-OMON46781Phase 3Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cefazolin in surgical site infection (SSI) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: fT>MIC at the target site. Planned start May 2018; status: withdrawn.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NL-OMON46781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46781.